Search results
Showing 16 to 30 of 60 results for diabetic foot
clinical effectiveness of maggot debridement therapy in the debridement of diabetic foot ulcers? Any explanatory notes(if applicable)...
effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers? Any explanatory notes(if applicable) Source
educational models and psycho-behavioural interventions in prevention of diabetic foot complications? Any explanatory notes(if...
educational models and psycho-behavioural interventions in prevention of diabetic foot complications? Any explanatory notes(if...
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
NG19/1 Question Does intensive monitoring of people at risk of diabetic foot disease reduce the morbidity associated with developing the...
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging .
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13